Observational Study Evaluating Tezepelumab Treatment in Adults With Chronic Rhinosinusitis With Nasal Polyps in Russia

What this Trial Is About

This research aims to collect real-world data on the use and effects of tezepelumab in adults with Chronic Rhinosinusitis with Nasal Polyps CRSwNP, including those with or without asthma. Conducted across approximately 10 sites in Russia, the study observes participants who have started tezepelumab treatment within the past 4 weeks, outside of a controlled clinical trial setting. This observational study seeks to understand how tezepelumab is used and its impact in routine medical practice. Participants in this study are adults aged 18 years or older who have been prescribed tezepelumab according to local guidelines and have initiated treatment recently. The study involves collecting retrospective and prospective medical data without altering treatment. Tezepelumab use is monitored over time, with data gathered on disease status and symptoms at baseline and at Weeks 4, 24, and 52 after starting treatment. No additional treatments or interventions are administered as part of the study. During the one-year follow-up, participants medical records and symptom assessments are reviewed periodically to evaluate changes in nasal polyp status, nasal congestion, and quality of life using standardized tools like the Nasal Polyp Score and SNOT-22 questionnaire. Researchers also track healthcare use related to CRSwNP and asthma, laboratory parameters, and treatment duration. The study aims to provide insights into tezepelumab treatment patterns, symptom changes, and healthcare resource use in everyday clinical settings.

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia